In the evolving field of biochemical research, the LP17 peptide has garnered significant attention due to its specific role in modulating the Triggering Receptor Expressed on Myeloid cells-1 (TREM-1). As a researcher interested in molecular signaling, my exploration into this 17-amino by A Tammaro · 2017 · Cited by 286 — This peptide (LQVTDSGLYRCVIYHPP), called LP17, was shown to reduce an inflammatory response in monocytes, induced by LPS or TREM-1 agonistic antibody (Gibot acid sequence (LQVTDSGLYRCVIYHPP) reveals why it remains a cornerstone in experimental studies involving inflammatory pathways and c The TREM1 decoy peptide LP17 reduces stroke injury Mice underwent MCAo and were administered LP17 or scrambled peptides either at reperfusion (t = 0 h) or ellular responses.
Understanding the LP17 Peptide Profile
The LP17 peptide is a synthetic molecule by C Li · 2024 · Cited by 59 — LP17 is one of the first peptides developed to inhibit TREM1 and is widely used in experimental research. It is a 17-amino acid synthetic peptide derived from a derived from the extracellular domain of the TREM-1 receptor. By acting as a competitive antagonist, LP17 effectively serves as a decoy, preventing the receptor from binding to its natural ligands. This mechanism is crucial for researchers investigating how to downregulate excessive immune responses in various experimental models.
When discussing peptides of this nature, it is essential to distinguish them from other compounds found in scientific literature, such as Petrelintide, which is an invest by AB Sigalov · 2014 · Cited by 93 — Collectively, our findings complement recently published data on antitumor activity of a TREM-1 antagonist LP-17 observed in a mouse model of colitis-induced igational long-acting amylin analog, or LTI-03, a first-in-class peptide derived from Caveolin-1. Unlike these, the LP17 peptide is primarily studied for its ability to block TREM-1 signaling.
Experimental Observations and Findings
My review of current data highlights several key areas where this compound is utilized:
* Neurological Research: Studies have shown that LP17 TFA substantially alleviates ischemia-induced infarction and neuronal injury. In these models, researchers often utilize LP17 (0.5 or 1 mg/kg; intranasal; daily for 3 days) to observe its ability to cross biological barriers and mitigate damage.
* Inflammatory Modulation: Evidence suggests that LP17 also ameliorated sepsis-induced acute lung injury, leading to improved outcomes in controlled study environments. Furthermore, the application of LP17 has been documented to have decreased the expression levels of pro-inflammatory genes in various infection models.
* Decoy Mechanism: As a highly pure TREM1 peptide, it functions as a competitive inhibitor. Because LP17 is one of the first peptides developed to inhibit TREM1, it provides a foundational benchmark for testing new, more stable variants.
Handling and Research Best Practices
For those working with peptides LP17 in a laboratory setting, proper handling is paramount. Researchers often reference specific protocols for reconstitution. For instance, dissolving the compound typically requires high-purity water, with pH adjustments (often using HCl) and ultrasonic treatment sometimes recommended to ensure complete solubility.
It is important to note that LP17 (human) is a TREM1 antagonist Feb 23, 2026 — We showed that natural peptides are promising molecules with drug-like properties and have implemented technologies to use them as bioactive peptide specifically designed for research use. It is distinct from substances like erythropoietin, which is the hormone involved in red blood cell production, or the various peptides used in cosmetic or nutritional studies.
Comparative Context in Modern Science
The utility of the LP-17 sequence extends to its role in competitive inhibition. By acting as a LP17 blocking peptide, it allows scientists to isolate the effects of TREM-1 activation. This is a critical distinction, as LP17 reduces stroke injury in experimental mouse models, demonstrating a clear therapeutic potential that warrants further rigorous investigation.
When comparing LP17 to other emerging molecules, it is clear that the specificity of this 17-amino acid peptide remains its greatest asset. Whether the goal is to evaluate TREM-1 blockade by the use of an inhibitory peptide LP17 or to study the broader implications of myeloid cell signaling, the molecule continues Protagonist Introduces Oral Peptide IL-17 Antagonist PN-881 to be a primary tool for those focused on the next frontier of biochemical research.
*Disclaimer: This article is for informational purposes for research professionals only. It does not provide medical advice or instructions for human consumption.* Peptide Therapeutics for Autoimmune and Inflammatory